Biosynth announced on July 11, 2023 that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer-based drug delivery excipients, according to a company press release. The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
